旭輝永升服務(01995.HK)料於4月底前刊發去年度業績 續停牌
旭輝永升服務(01995.HK)公布,核數師近日收到一封匿名信函,指控公司與大股東旭輝控股(00884.HK)進行的若干交易涉資18億元人民幣,由於有關指控含糊不清,缺乏實質內容,管理層已對信函中所述交易進行審查,認為該等交易已在集團管理賬目中適當記錄,具有充分的商業事實及業務理據,並按正常商業條款進行。
董事會及管理層將繼續與核數師緊密合作,以促進完成剩餘的審核程式,預期於今年4月30日或之前刊發2022年全年業績及寄發2022年年度報告。
應公司要求,股份已於2023年3月31日起暫停在聯交所買賣,並將繼續暫停,直至刊發2022年全年業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.